BioSpace News Archive

The Best Biotech Entrepreneur Award® goes to Gilles Avenard, CEO of Acticor Biotech

Researchers published an article in the journal Nature Ecology & Evolution that described preliminary findings of gene variants in George associated with a strong immune system, efficient DNA repair and cancer resistance.

There is very little doubt that developing drugs for neuroscience disorders in general and dementias in particular is a high-risk business. Axovant Sciences, unfortunately, seems to be finding that out the hard way.

At its San Diego site, the company plans to establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D, which will also include Phase I GMP manufacturing.

Pharming Group N.V. today acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).

The U.S. Food and Drug Administration (FDA) has issued an approval letter for the new features and intended uses of the Planmed Verity® CBCT scanner. Planmed is very pleased to bring these exciting improvements to the U.S. market.

Hosted by UBM Sinoexpo

Bristol-Myers Squibb Company and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a rationally-defined human bacterial consortium, in patients with advanced or metastatic cancers.

Alnylam Pharmaceuticals, Inc. announced today that it has resolved all litigation worldwide with Silence Therapeutics.

Over 91,000 doses of rimegepant 75mg administered across 1,780 patients with migraine